Altering duration of the presynchronization period in a long-term progestin-based estrus synchronization protocol for timed artificial insemination of beef heifers.

An experiment was designed to evaluate the effect of extending duration of the presynchronization treatment in a long-term progestin-based estrus synchronization protocol. Heifers were assigned to either an 18 d (Day 0-18) or 14 d (Day 4 to Day 18) CIDR® treatment (1.38 g progesterone controlled internal drug release insert; Zoetis, Madison, NJ), with prostaglandin F2α (PG; 250 μg im cloprostenol sodium) administered 16 d after CIDR® removal (Day 34). Heifers at two locations (location one, n = 193; location two, n = 649) were assigned to treatment based on reproductive tract score (RTS; Scale 1-5) and body weight. Heifers that were assigned RTS 1 were not retained for the trial (n = 6). Estrus detection aids (Estrotect®) were applied at PG. Split-time artificial insemination (STAI) was utilized and AI performed based on expression of estrus at 66 h. Expression of estrus was defined as removal of ≥50% of the grey coating from the Estrotect® patch. Heifers that expressed estrus at 66 h were inseminated then and heifers that had not expressed estrus were inseminated at 90 h. Only heifers that failed to express estrus by 90 h received gonadotropin-releasing hormone (GnRH; 100 μg im gonadorelin acetate) at the time of AI. At location one, blood samples were collected at PG and AI (66 h or 90 h) from all heifers to determine E2 concentration by radioimmunoassay, and transrectal ovarian ultrasound was performed to detail ovarian structures on a subset of heifers (n = 73) at both time points. The proportion of heifers expressing estrus did not differ between treatments, either by 66 h (60%) or in total by 90 h (84%) after PG. Pregnancy rate to STAI did not differ between treatments (P = 0.3; 52%, 14-d CIDR®-PG; 50%, 18-d CIDR®-PG), or at the end of the 60 d breeding season (P = 0.2; 86%, 14-d CIDR®-PG; 82%, 18-d CIDR®-PG). No differences were detected in mean diameter of the dominant follicle at PG (P = 0.6; 10.9 ± 0.4 mm, 14-d CIDR®-PG; 11.0 ± 0.4 mm, 18-d CIDR®-PG) or at STAI (P = 0.3; 12.6 ± 0.4 mm, 14-d CIDR®-PG; 13.2 ± 0.4 mm, 18-d CIDR®-PG), nor were any differences observed between treatments in concentrations of E2 at PG (P = 0.8; 1.1 ± 0.19 pg/ml, 14-d CIDR®-PG; 1.1 ± 0.19 pg/ml, 18-d CIDR®-PG) or STAI (P = 0.6; 3.8 ± 0.19 pg/ml, 14-d CIDR®-PG; 3.6 ± 0.19 pg/ml, 18-d CIDR®-PG). These data indicate that duration of CIDR® treatment can be extended from 14 to 18 d, thus providing flexibility in scheduling without compromising reproductive outcomes.